Alpine Immune Sciences, INC.: directors' dealings · United States · SEC (Form 4)

About Alpine Immune Sciences, INC.

Alpine Immune Sciences, Inc. was a U.S.-listed biotechnology company traded on NASDAQ (NASDAQ: ALPN) and based in the United States. Its principal operating footprint was in Seattle, Washington, giving it a clear place in the U.S. biopharma cluster. Alpine built its identity around the discovery and development of innovative, protein-based immunotherapies, with a particular emphasis on autoimmune and inflammatory diseases. For equity investors, it represented a classic clinical-stage biotech profile: a science-driven company whose valuation was closely tied to pipeline data, platform credibility, and strategic partnering potential. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1626199/0001626199-24-000048-index.htm?utm_source=openai)) The company’s core business was centered on protein engineering and immunology. Alpine’s approach focused on designing therapeutics that could precisely modulate immune pathways rather than broadly suppress immune function. Its lead asset, povetacicept (also referred to as ALPN-303), was the flagship program and was positioned as a potentially differentiated immunology asset with the ability to address multiple diseases. Alpine described the program as having “pipeline-in-a-product” potential, a term that captures the idea that one molecule could support multiple commercial indications if the clinical and regulatory data remain favorable. The company also advanced earlier-stage programs and had collaborated with larger biopharmaceutical partners, which helped validate its scientific platform and broaden development optionality. ([nasdaq.com](https://www.nasdaq.com/press-release/vertex-enters-into-agreement-to-acquire-alpine-immune-sciences-2024-04-10?utm_source=openai)) In competitive terms, Alpine operated in one of the most demanding areas of healthcare investing: specialty biotech. The company’s competitive edge was not scale, manufacturing breadth, or commercial reach, but the quality of its underlying biology, the novelty of its mechanism, and the breadth of its therapeutic pipeline. Its focus on serious autoimmune and inflammatory conditions placed it in a market where differentiation depends on efficacy, selectivity, and the ability to generate strong human data early. For investors, that meant the story was highly binary: positive clinical readouts could materially increase strategic value, while setbacks could rapidly compress valuation. ([nasdaq.com](https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-update-on-alpn-303-a-dual-baff-april-inhibitor-for?utm_source=openai)) The most important recent corporate event was Vertex Pharmaceuticals’ announcement on April 10, 2024 that it had entered into a definitive agreement to acquire Alpine for $65 per share in cash, valuing the transaction at roughly $4.9 billion. That announcement effectively transformed Alpine from a standalone small-cap biotech into a strategic asset targeted by a major global pharma company. For market participants, the deal underscored the perceived quality of Alpine’s immunology platform and the attractiveness of povetacicept as a lead asset. ([nasdaq.com](https://www.nasdaq.com/press-release/vertex-enters-into-agreement-to-acquire-alpine-immune-sciences-2024-04-10?utm_source=openai)) Overall, Alpine Immune Sciences was best understood as a U.S. clinical-stage immunology biotech listed on NASDAQ, with Seattle roots, a focused therapeutic pipeline, and a recent headline acquisition by Vertex. For French-, Belgian-, and Swiss-based investors, the case highlights the combination of scientific upside, clinical execution risk, and M&A optionality that defines many U.S. biotech equities.